Adan Perez-Arredondo

Dr. Adan Perez-Arredondo

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMarina Martínez
Marina Martínez
JMJulio Morales-Gomez
Julio Morales-Gomez
RGRuben Gonzalez-Rivera
Ruben Gonzalez-Rivera
CHCarla Hernandez-Enriquez
Carla Hernandez-Enriquez
APAdan Perez-Arredondo
Adan Perez-Arredondo
LNLuz Navarro
Luz Navarro
The endocannabinoid system is a component of the neuroprotective mechanisms that an organism displays after traumatic brain injury (TBI). A diurnal variation in several components of this system has been reported. This variation may influence the recovery and survival rate after TBI. We have previously reported that the recovery and survival rate of rats is higher if TBI occurs at 1:00 than at 13:00. This could be explained by a diurnal variation of the endocannabinoid system. Here, we describe the effects of anandamide administration in rats prior to the induction of TBI at two different times of the day: 1:00 and 13:00. We found that anandamide reduced the neurological damage at both times. Nevertheless, its effects on bleeding, survival, food intake, and body weight were dependent on the time of TBI. In addition, we analyzed the diurnal variation of the expression of the cannabinoid receptors CB1R and CB2R in the cerebral cortex of both control rats and rats subjected to TBI. We found that CB1R protein was expressed more during the day, whereas its mRNA level was higher during the night. We did not find a diurnal variation for the CB2R. In addition, we also found that TBI increased CB1R and CB2R in the contralateral hemisphere and disrupted the CB1R diurnal cycle.

1 November 2012 in Neuroscience Letters
Verified
Journal Article
Closed access
MMMarina Martínez
Marina Martínez
FRFrancisco Estrada Rojo
Francisco Estrada Rojo
ETErika Tabla-Ramon
Erika Tabla-Ramon
HNHilda Navarro-Argüelles
Hilda Navarro-Argüelles
NONathan Ortiz-Lailzon
Nathan Ortiz-Lailzon
LNLuz Navarro
Luz Navarro

1 November 2016 in Clinical Neuropharmacology
Verified
Journal Article
Open access
APAdan Perez-Arredondo
Adan Perez-Arredondo
ECEduardo Cázares-Ramírez
Eduardo Cázares-Ramírez
PCPaul Carrillo-Mora
Paul Carrillo-Mora
MMMarina Martínez
Marina Martínez
Noemi Cardenas-RodríguezNoemi Cardenas-Rodríguez
Noemi Cardenas-Rodríguez
LCLiliana Carmona-Aparicio
Liliana Carmona-Aparicio
Traumatic brain injury (TBI) is an alteration in brain function, caused by an external force, which may be a hit on the skull, rapid acceleration or deceleration, penetration of an object, or shock waves from an explosion. Traumatic brain injury is a major cause of morbidity and mortality worldwide, with a high prevalence rate in pediatric patients, in which treatment options are still limited, not available at present neuroprotective drugs. Although the therapeutic management of these patients is varied and dependent on the severity of the injury, general techniques of drug types are handled, as well as physical and surgical. Baclofen is a muscle relaxant used to treat spasticity and improve mobility in patients with spinal cord injuries, relieving pain and muscle stiffness. Pharmacological support with baclofen is contradictory, because disruption of its oral administration may cause increased muscle tone syndrome and muscle spasm, prolonged seizures, hyperthermia, dysesthesia, hallucinations, or even multisystem organ failure. Combined treatments must consider the pathophysiology of broader alterations than only excitation/inhibition context, allowing the patient's reintegration with the greatest functionality.

Verified
Journal Article
Open access
PDF file
MMMarina Martínez
Marina Martínez
MSMaribel Soto-Nuñez
Maribel Soto-Nuñez
ETErika Tabla-Ramon
Erika Tabla-Ramon
BSBarbara Solis
Barbara Solis
RGRuben Gonzalez-Rivera
Ruben Gonzalez-Rivera
LNLuz Navarro
Luz Navarro
Cathepsin B is one of the major lysosomal cysteine proteases involved in neuronal protein catabolism. This cathepsin is released after traumatic injury and increases neuronal death; however, release of cystatin C, a cathepsin inhibitor, appears to be a self-protective brain response. Here we describe the effect of cystatin C intracerebroventricular administration in rats prior to inducing a traumatic brain injury. We observed that cystatin C injection caused a dual response in post-traumatic brain injury recovery: higher doses (350 fmoles) increased bleeding and mortality, whereas lower doses (3.5 to 35 fmoles) decreased bleeding, neuronal damage and mortality. We also analyzed the expression of cathepsin B and cystatin C in the brains of control rats and of rats after a traumatic brain injury. Cathepsin B was detected in the brain stem, cerebellum, hippocampus and cerebral cortex of control rats. Cystatin C was localized to the choroid plexus, brain stem and cerebellum of control rats. Twenty-four hours after traumatic brain injury, we observed changes in both the expression and localization of both proteins in the cerebral cortex, hippocampus and brain stem. An early increase and intralysosomal expression of cystatin C after brain injury was associated with reduced neuronal damage.

29 November 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LVLeticia Verdugo-Diaz
Leticia Verdugo-Diaz
FEFrancisco Estrada-Rojo
Francisco Estrada-Rojo
AGAron Garcia-Espinoza
Aron Garcia-Espinoza
EHEduardo Hernandez-Lopez
Eduardo Hernandez-Lopez
AHAlejandro Hernandez-Chavez
Alejandro Hernandez-Chavez
LNLuz Navarro
Luz Navarro
Traumatic brain injury (TBI) represents a significant public health concern and has been associated with high rates of morbidity and mortality. Although several research groups have proposed the use of repetitive transcranial magnetic stimulation (rTMS) to enhance neuroprotection and recovery in patients with TBI, few studies have obtained sufficient evidence regarding its effects in this population. Therefore, we aimed to analyze the effect of intermediate-frequency rTMS (2 Hz) on behavioral and histological recovery following TBI in rats. Male Wistar rats were divided into six groups: three groups without TBI (no manipulation, movement restriction plus sham rTMS, and movement restriction plus rTMS) and three groups subjected to TBI (TBI only, TBI plus movement restriction and sham rTMS, and TBI plus movement restriction and rTMS). The movement restriction groups were included so that rTMS could be applied without anesthesia. Our results indicate that the restriction of movement and sham rTMS per se promotes recovery, as measured using a neurobehavioral scale, although rTMS was associated with faster and superior recovery. We also observed that TBI caused alterations in the CA1 and CA3 subregions of the hippocampus, which are partly restored by movement restriction and rTMS. Our findings indicated that movement restriction prevents damage caused by TBI and that intermediate-frequency rTMS promotes behavioral and histologic recovery after TBI.

9 September 2017 in Reviews in the Neurosciences
Verified
Journal Article
Closed access
PDF file
FEFrancisco Estrada-Rojo
Francisco Estrada-Rojo
RMRicardo Jesús Martínez-Tapia
Ricardo Jesús Martínez-Tapia
FEFrancisco Estrada-Bernal
Francisco Estrada-Bernal
MMMarina Martínez
Marina Martínez
APAdan Perez-Arredondo
Adan Perez-Arredondo
LNLuz Navarro
Luz Navarro
Traumatic brain injury (TBI) is a contemporary health problem and a leading cause of mortality and morbidity worldwide. Survivors of TBI frequently experience disabling long-term changes in cognition, sensorimotor function, and personality. A crucial step in understanding TBI and providing better treatment has been the use of models to mimic the event under controlled conditions. Here, we describe the known head injury models, which can be classified as whole animal (in vivo),in vitro, and mathematical models. We will also review the ways in which these models have advanced the knowledge of TBI.